+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 4 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.

Age: 18Years +All GendersPhase 3
1452 locations
S

Actively Recruiting

Researchers are investigating the use of endoscopic surgery as a less invasive alternative to traditional lumbar spine fusion for patients with spinal stenosis and spondylolisthesis. This approach aims to decompress the lumbar spine while preserving its natural function and stability, potentially reducing the need for spinal fusion. The study explores whether endoscopic techniques can lower the rate of more invasive surgical interventions in this population. The study focuses on patients who require spinal decompression surgery and are considered for endoscopic procedures. It observes outcomes related to these minimally destructive surgical methods without introducing experimental drugs or devices. The main goal is to evaluate the rate of surgical reintervention within one year after the initial endoscopic surgery. Participants will be monitored over time to assess if further surgical procedures are needed. Researchers will review medical imaging and clinical data to understand the effectiveness of endoscopic decompression in avoiding fusion surgery. The study involves adults 18 years and older and tracks outcomes related to surgical reintervention during the follow-up period, with participation potentially lasting up to several years.

Age: 18Years +All Genders
13 locations
I

Actively Recruiting

Fever is a common reason for children aged 3 months to 15 years to visit healthcare providers. It can be hard to tell if the fever is caused by a viral or bacterial infection just by examining the child, which sometimes requires additional tests like measuring C-reactive protein CRP. This study looks at using a capillary medical device to measure CRP directly in primary care to help reduce unnecessary referrals to emergency rooms and labs, improving care for febrile children and easing healthcare system burdens. The study compares two groups one using capillary CRP measurement with the ACTIM-CRP device and a control group without this intervention. Children are randomly assigned to these groups during their primary care visit when they have a fever that meets specific duration and severity conditions. The study runs from September 2025 to June 2027 and focuses on referral rates and other outcomes related to care pathways for febrile children. Participants will be involved in the study during their initial consultation and followed up for up to seven days to monitor referrals, antibiotic prescriptions, satisfaction of both general practitioners and parents, fever duration, and cost impacts. Data on complementary tests and healthcare usage will also be collected to understand the effects of using capillary CRP testing in primary care. The study aims to improve the efficiency and quality of care for children with fever.

Age: 3Months - 15YearsAll GendersPhase Not Applicable
37 locations
E

Actively Recruiting

Researchers are evaluating the combination of baxdrostat and dapagliflozin compared with dapagliflozin alone in adults aged 40 years and older who have type 2 diabetes, established cardiovascular disease, a history of hypertension with elevated systolic blood pressure, and at least one additional risk factor for heart failure. This phase III trial aims to assess whether adding baxdrostat can reduce the risk of heart failure events or cardiovascular death. Participants will be randomly assigned to receive either baxdrostat with dapagliflozin or placebo with dapagliflozin. Those not currently on SGLT2 inhibitors or treated for less than 4 weeks will enter a run-in period taking dapagliflozin alone for 4 to 6 weeks before randomization. Doses of baxdrostat may be increased if criteria are met. Study visits occur at 2, 4, 8, 16, and 34 weeks after randomization and then approximately every 4 months until the study ends when enough cardiovascular events have occurred. During the study, participants will have regular assessments including blood pressure and laboratory tests to monitor safety and efficacy. If participants stop the blinded study treatment early, they may continue open-label dapagliflozin. The main outcome is to see if the combination reduces heart failure events or cardiovascular death compared to dapagliflozin alone, with follow-up lasting up to 38 months. Data collection and scheduled visits will continue throughout the study period.

Age: 40Years +All GendersPhase 3
977 locations